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The vanguard heart failure (HF) registry in India demonstrated significantly lower 5- year mortal-ity rates for patients with HF with reduced ejec-
tion fraction (HFrEF) discharged on guideline- directed 
medical therapy (GDMT), revealing an important target 
for intervention to improve clinical outcomes.1 Hospital- 
based quality improvement initiatives to increase rates 
of GDMT at hospital discharge have had limited ef-
fect, suggesting additional strategies are needed to 
improve GDMT rates in patients with HFrEF.2 Polypills 
for HFrEF have been proposed as an implementation 
strategy to simplify the current treatment paradigm for 
undertreated patients with HFrEF.3 However, the po-
tential effect of HFrEF polypills on increasing GDMT 
rates in target populations is unknown. The objective 
of this secondary analysis of a prospective, interrupted 
times series study is to describe eligibility for a poten-
tial HFrEF polypill in the context of GDMT prescription 
rates for patients with HFrEF who were discharged 
from 8 hospitals in South India.
The HF QUIK (Heart Failure Quality Improvement in 
Kerala) study was a prospective, interrupted time se-
ries study using longitudinal data from February 2018 
to August 2018 that evaluated the effect of a quality im-
provement intervention on process of care measures 
and clinical outcomes in patients hospitalized with 
acute HF in 8 hospitals in South India.4 Patients 
were eligible for inclusion if they were (1) adults aged 
≥18 years, and (2) met at least 2 criteria for diagnosis of 
HF as defined by the European Society of Cardiology 
(clinical symptoms and signs of HF, natriuretic peptide 
elevation, or echocardiographic evidence of left ven-
tricular systolic or diastolic dysfunction). The HF QUIK 
quality improvement intervention consisted of check-
lists, audit and feedback reports with site- specific per-
formance measures, and patient education materials. 
The control period consisted of usual care according 
to local hospital practice. Participants were allocated 
to the control (February 2018 to May 2018) or inter-
vention period (May 2018 to August 2018) based on 
hospital admission date. The study protocol was re-
viewed by and received ethics board approval from 
Duke University (Durham, NC), Centre for Chronic 
Disease Control (New Delhi, Delhi, India), Cardiological 
Society of India- Kerala Chapter (Kochi, Kerala, India), 
and Indian Health Ministry Screening Committee (New 
Delhi, Delhi, India) in November 2017. Because data 
were used at the local hospitals for the purpose of 
quality improvement, sites were granted a waiver of 
informed consent under the Common Rule. The data 
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that support the findings of this study are available from 
the corresponding author upon reasonable request.
Participants with HFrEF with left ventricular ejection 
fraction <40% were included in this secondary analy-
sis. The primary outcome was prescription of GDMT 
defined as an angiotensin- converting enzyme inhibitor 
or angiotensin receptor blocker or angiotensin recep-
tor neprilysin inhibitor, along with a beta blocker and 
aldosterone antagonist, measured separately and as 
a combined outcome. Additional outcomes included 
prescription of loop and thiazide diuretic. Participants 
were eligible for a HFrEF polypill containing GDMT in-
cluding angiotensin- converting enzyme inhibitor or 
angiotensin receptor blocker or angiotensin receptor 
neprilysin inhibitor, beta blocker, and aldosterone an-
tagonist at hospital discharge if left ventricular ejection 
fraction <40%, heart rate ≥50 beats/min, serum cre-
atinine ≤2.5 mg/dL in men and ≤2 mg/dL in women, 
and serum potassium <5 mEq/L. Creatinine thresholds 
were based on guideline- recommended thresholds for 
aldosterone antagonists. Categorical variables were 
reported as counts with percentages, and we per-
formed a complete case analysis due to low rate of 
missing data. The difference in proportions between 
medication at admission and discharge for control and 
intervention periods was calculated using chi- square 
test. We used R software (version 4.0.3, R Foundation, 
Vienna, Austria) for statistical analyses.
We included 937 participants with HFrEF (n=494 
control period, n=443 intervention period). The Table 
illustrates prescription of medications for HF at admis-
sion (reflecting medications participants were on before 
admission) and at hospital discharge by control and 
intervention periods. Prescription rates of angiotensin- 
converting enzyme inhibitor or angiotensin receptor 
blocker or angiotensin receptor neprilysin inhibitor, 
beta blocker, and aldosterone antagonists were low 
on hospital admission and increased at hospital dis-
charge. The rate of loop diuretic prescription increased 
at discharge. The prescription of GDMT increased 
from 5.5% to 28.8% in the control period and from 
4.5% to 42.3% in the intervention period. More than 
80% of participants were eligible for a HFrEF polypill at 
hospital discharge during both control (n/N=364/494) 
and intervention (n/N=336/443) periods, with similar 
rates among female and male participants.
In the HF QUIK study population, more than 80% 
of patients were eligible for a HFrEF polypill at dis-
charge. Although the HF QUIK quality improvement 
intervention increased rates of GDMT at hospital 
Table. Medication Prescription and HFrEF Polypill Eligibility of HF QUIK Participants by Control and Intervention Periods
Control period*   
N=494
P value












ACE- I or ARB or 
ARNi
123 (24.9%) 208 (47.2%) <0.01 104 (23.5%) 211 (52.2%) <0.01
Beta- blocker 152 (30.8%) 333 (75.5%) <0.01 159 (35.9%) 332 (82.2%) <0.01
Aldosterone 
antagonist
94 (19.0%) 286 (64.9%) <0.01 61 (13.8%) 305 (75.5%) <0.01
Loop diuretic 197 (39.9%) 409 (92.7%) <0.01 177 (40.0%) 396 (98.0%) <0.01
Thiazide diuretic 8 (1.6%) 9 (2.0%) 0.63 6 (1.4%) 8 (2.0%) 0.48
GDMT† 27 (5.5%) 127 (28.8%) <0.01 20 (4.5%) 171 (42.3%) <0.01
HFrEF polypill eligibility at discharge‡
Control period: discharge  
N=441 (F: 164, M: 277)
Intervention period: discharge  
N=404 (F: 127, M: 277)
Total§ 364 (82.5%) 336 (83.2%) 0.81#
Female|| 133 (81.1%) 0.54** 100 (78.7%) 0.11**
Male|| 231 (83.4%) 236 (85.2%)
ACE- I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor neprilysin inhibitor; GMDT, guideline- 
directed medical therapy; and HFrEF, heart failure with reduced ejection fraction.
*Among participants with LVEF <40%.
†Defined as ACE- I or ARB or ARNi+beta- blocker+aldosterone antagonist.
‡Eligible participants meet the following criteria: LVEF <40%, heart rate ≥50 beats/min, serum creatinine ≤2.5 mg/dL in men and ≤2 mg/dL in women, serum 
potassium <5 mEq/L.
§Percentages indicate proportion out of total discharged participants in control (n=441) and intervention (n=404) periods.
||Percentages indicate proportion of females and males participants eligible for a HFrEF polypill among total females and males participants at hospital 
discharge in the control and intervention periods.
#P- value indicates difference between HFrEF polypill eligibility during control period and intervention periods.
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discharge from 28.8% in the control period to 42.3% 
in the intervention period, routine administration of a 
HFrEF polypill could increase this rate and improve 
adherence by 44% (95% CI, 26%– 65%) in a popu-
lation that remains undertreated despite targeted 
quality improvement interventions.4,5 Availability of 
multiple HFrEF polypill doses could prioritize safety 
and tolerability with low- dose initiation and subse-
quent titration to higher- dose polypills. An import-
ant limitation of this analysis is that laboratory values 
used to determine polypill eligibility at discharge were 
obtained at time of hospital admission, although renal 
function frequently changes during hospitalization in 
many patients with HF. Efficacy, safety, and effec-
tiveness of HFrEF polypills initiated at discharge and 
titrated in outpatient settings will need to be estab-
lished in rigorous randomized trials.3 This analysis 
demonstrates high potential rates of HFrEF polypill 
eligibility and suggests a simplified polypill- based 
management strategy could be transformative for 
closing the treatment gap in HFrEF inequities in India 
and globally.
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